1092 related articles for article (PubMed ID: 27588937)
1. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.
Tebben PJ; Singh RJ; Kumar R
Endocr Rev; 2016 Oct; 37(5):521-547. PubMed ID: 27588937
[TBL] [Abstract][Full Text] [Related]
2. CYP24A1 loss of function: Clinical phenotype of monoallelic and biallelic mutations.
Carpenter TO
J Steroid Biochem Mol Biol; 2017 Oct; 173():337-340. PubMed ID: 28093352
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect.
O'Keeffe DT; Tebben PJ; Kumar R; Singh RJ; Wu Y; Wermers RA
Osteoporos Int; 2016 Oct; 27(10):3121-5. PubMed ID: 27129455
[TBL] [Abstract][Full Text] [Related]
4. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations.
Figueres ML; Linglart A; Bienaime F; Allain-Launay E; Roussey-Kessler G; Ryckewaert A; Kottler ML; Hourmant M
Am J Kidney Dis; 2015 Jan; 65(1):122-6. PubMed ID: 25446019
[TBL] [Abstract][Full Text] [Related]
5. 1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis.
Nesterova G; Malicdan MC; Yasuda K; Sakaki T; Vilboux T; Ciccone C; Horst R; Huang Y; Golas G; Introne W; Huizing M; Adams D; Boerkoel CF; Collins MT; Gahl WA
Clin J Am Soc Nephrol; 2013 Apr; 8(4):649-57. PubMed ID: 23293122
[TBL] [Abstract][Full Text] [Related]
6. Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis.
Dinour D; Beckerman P; Ganon L; Tordjman K; Eisenstein Z; Holtzman EJ
J Urol; 2013 Aug; 190(2):552-7. PubMed ID: 23470222
[TBL] [Abstract][Full Text] [Related]
7. Maternal Hypercalcemia Due to Failure of 1,25-Dihydroxyvitamin-D3 Catabolism in a Patient With CYP24A1 Mutations.
Shah AD; Hsiao EC; O'Donnell B; Salmeen K; Nussbaum R; Krebs M; Baumgartner-Parzer S; Kaufmann M; Jones G; Bikle DD; Wang Y; Mathew AS; Shoback D; Block-Kurbisch I
J Clin Endocrinol Metab; 2015 Aug; 100(8):2832-6. PubMed ID: 26097993
[TBL] [Abstract][Full Text] [Related]
8. Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: A cross-sectional study.
Cools M; Goemaere S; Baetens D; Raes A; Desloovere A; Kaufman JM; De Schepper J; Jans I; Vanderschueren D; Billen J; De Baere E; Fiers T; Bouillon R
Bone; 2015 Dec; 81():89-96. PubMed ID: 26117226
[TBL] [Abstract][Full Text] [Related]
9. CYP24A1 Mutations in a Cohort of Hypercalcemic Patients: Evidence for a Recessive Trait.
Molin A; Baudoin R; Kaufmann M; Souberbielle JC; Ryckewaert A; Vantyghem MC; Eckart P; Bacchetta J; Deschenes G; Kesler-Roussey G; Coudray N; Richard N; Wraich M; Bonafiglia Q; Tiulpakov A; Jones G; Kottler ML
J Clin Endocrinol Metab; 2015 Oct; 100(10):E1343-52. PubMed ID: 26214117
[TBL] [Abstract][Full Text] [Related]
10. CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations.
Hawkes CP; Li D; Hakonarson H; Meyers KE; Thummel KE; Levine MA
J Clin Endocrinol Metab; 2017 May; 102(5):1440-1446. PubMed ID: 28324001
[TBL] [Abstract][Full Text] [Related]
11. Iatrogenic vitamin D toxicity in an infant--a case report and review of literature.
Ketha H; Wadams H; Lteif A; Singh RJ
J Steroid Biochem Mol Biol; 2015 Apr; 148():14-8. PubMed ID: 25636720
[TBL] [Abstract][Full Text] [Related]
12. [A young girl with recurrent calculosis and hypercalcemia].
Di Maio F; Vittori M; Bassi P; Fulignati P; D'Alonzo S; Ferraro PM
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786188
[TBL] [Abstract][Full Text] [Related]
13. LC-MS/MS for Identifying Patients with CYP24A1 Mutations.
Ketha H; Kumar R; Singh RJ
Clin Chem; 2016 Jan; 62(1):236-42. PubMed ID: 26585929
[TBL] [Abstract][Full Text] [Related]
14. Infantile hypercalcemia and hypercalciuria: new insights into a vitamin D-dependent mechanism and response to ketoconazole treatment.
Nguyen M; Boutignon H; Mallet E; Linglart A; Guillozo H; Jehan F; Garabedian M
J Pediatr; 2010 Aug; 157(2):296-302. PubMed ID: 20394945
[TBL] [Abstract][Full Text] [Related]
15. Novel CYP24A1 Mutation in a Young Male Patient with Nephrolithiasis: Case Report.
Jiráčková J; Hyšpler R; Alkanderi S; Pavlíková L; Palicka V; Sayer JA
Kidney Blood Press Res; 2019; 44(4):870-877. PubMed ID: 31288237
[TBL] [Abstract][Full Text] [Related]
16. Hypervitaminosis D Secondary to a
Collins L; Boehm E; Luxford C; Clifton-Bligh R; Grill V
JBMR Plus; 2023 Sep; 7(9):e10788. PubMed ID: 37701149
[TBL] [Abstract][Full Text] [Related]
17. Mild Idiopathic Infantile Hypercalcemia-Part 1: Biochemical and Genetic Findings.
Lenherr-Taube N; Young EJ; Furman M; Elia Y; Assor E; Chitayat D; Uster T; Kirwin S; Robbins K; Vinette KMB; Daneman A; Marshall CR; Collins C; Thummel K; Sochett E; Levine MA
J Clin Endocrinol Metab; 2021 Sep; 106(10):2915-2937. PubMed ID: 34125233
[TBL] [Abstract][Full Text] [Related]
18. Do the Heterozygous Carriers of a CYP24A1 Mutation Display a Different Biochemical Phenotype Than Wild Types?
Brancatella A; Cappellani D; Kaufmann M; Borsari S; Piaggi P; Baldinotti F; Caligo MA; Jones G; Marcocci C; Cetani F
J Clin Endocrinol Metab; 2021 Mar; 106(3):708-717. PubMed ID: 33249478
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia, nephrolithiasis, and hypervitaminosis D precipitated by supplementation in a susceptible individual.
Haridas K; Holick MF; Burmeister LA
Nutrition; 2020 Jun; 74():110754. PubMed ID: 32222584
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of vitamin D-related hypercalcemia using serum vitamin D metabolite profiling.
Kaufmann M; Schlingmann KP; Berezin L; Molin A; Sheftel J; Vig M; Gallagher JC; Nagata A; Masoud SS; Sakamoto R; Nagasawa K; Uesugi M; Kottler ML; Konrad M; Jones G
J Bone Miner Res; 2021 Jul; 36(7):1340-1350. PubMed ID: 33856702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
